Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04682431 · ClinicalTrials.gov registry record · Phase 1
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Ikena Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
NCT04682431 is a Phase 1 study that was terminated before completion, run by Ikena Oncology. The registered enrollment target is 127 participants.
The verdict
NCT04682431, a Phase 1 study, was terminated before completion, sponsored by Ikena Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).
Interventions
- DRUG PY159 Single agent dose level 1
- DRUG PY159 Single agent dose level 2
- DRUG PY159 Single agent dose level 3
- DRUG PY159 Single agent dose level 4
- DRUG PY159 Single agent dose level 5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2020-11-10 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04682431
The ClinicalTrials.gov registry entry for NCT04682431 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ikena Oncology, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which PY159 Single agent dose level 1 is the first listed.
NCT04682431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04682431 about?
NCT04682431 is a clinical study titled "A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors". This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).
What is the current status of trial NCT04682431?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2020-11-10. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT04682431?
The interventions under investigation include: PY159 Single agent dose level 1 (DRUG), PY159 Single agent dose level 2 (DRUG), PY159 Single agent dose level 3 (DRUG), PY159 Single agent dose level 4 (DRUG), PY159 Single agent dose level 5 (DRUG).
Who is sponsoring clinical trial NCT04682431?
This trial is sponsored by Ikena Oncology, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.